Decoy Therapeutics (DCOY) Non-Current Assets (2014 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Non-Current Assets of $65623.0 for Q1 2026, up 91.29% year-over-year from $34306.0 in Q1 2025, and down 8.28% quarter-over-quarter from $71547.0 in Q4 2025.
Decoy Therapeutics (DCOY) Non-Current Assets (2014 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Non-Current Assets for 13 consecutive years, with $65623.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 91.29% year-over-year to $65623.0; the TTM figure through Mar 2026 stood at $202464.0 (up 38.52% YoY), while the FY2025 annual figure was $71547.0, up 102.04% from the prior year.
- Non-Current Assets eased to $65623.0 in Q1 2026 per DCOY's latest filing, from $71547.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $10.7 million in Q1 2022 and bottomed at $32094.0 in Q3 2025.
- Historically, Non-Current Assets has averaged $1.4 million across 5 years, with a median of $66850.0 in 2023.
- Annual changes were most pronounced in 2023 — Non-Current Assets plunged 99.07% — and 2025, when it surged 102.04%.
- Decoy Therapeutics' Non-Current Assets stood at $130501.0 in 2022, then plunged by 48.77% to $66850.0 in 2023, then tumbled by 47.03% to $35412.0 in 2024, then jumped by 102.04% to $71547.0 in 2025, then fell by 8.28% to $65623.0 in 2026.
- Business Quant data shows DCOY's Non-Current Assets at $65623.0 in Q1 2026, $71547.0 in Q4 2025, and $32094.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | 427,852.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 427,852.00 |
| Mar 31, 2026 | 65,623.00 |
| Dec 31, 2025 | 71,547.00 |
| Sep 30, 2025 | 32,094.00 |
| Jun 30, 2025 | 33,200.00 |
| Mar 31, 2025 | 34,306.00 |
| Dec 31, 2024 | 35,412.00 |
| Sep 30, 2024 | 36,518.00 |
| Jun 30, 2024 | 39,931.00 |
| Mar 31, 2024 | 53,390.00 |
| Dec 31, 2023 | 66,850.00 |
| Sep 30, 2023 | 80,444.00 |
| Jun 30, 2023 | 99,048.00 |
| Mar 31, 2023 | 114,852.00 |
| Dec 31, 2022 | 130,501.00 |
| Sep 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 10.64 Mn |
| Mar 31, 2022 | 10.65 Mn |
| Dec 31, 2021 | 10.67 Mn |
| Sep 30, 2021 | 9.08 Mn |